Repair and regeneration of ocular tissue using postpartum-derived cells

Patent metadata

Field	Value
Publication number	US-10744164-B2
Application number	US-201614992431-A
Country	US
Kind code	B2
Filing date	Jan 11, 2016
Priority date	Jun 27, 2003
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

First claim

What is claimed is:

1. A method for promoting axonal regeneration in an optic nerve in a patient having optic nerve trauma comprising administering to the optic nerve isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to promote axonal regeneration, wherein the isolated umbilicus-derived cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

2. The method of claim 1 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141; and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

3. The method of claim 2 , wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

4. The method of claim 1 , wherein the isolated umbilicus-derived cells are expanded in culture prior to administering to the optic nerve.

5. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered with at least one other agent.

6. The method of claim 5 , wherein the at least one other agent is administered simultaneously with, or before, or after, the isolated umbilicus-derived cells.

7. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered through a cannula or from a device inserted in the patient's eye.

8. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered by insertion of a matrix or scaffold containing the cells.

9. A method for preserving the outer nuclear layer of a retina in a patient with retinal degeneration comprising administering to the interior of the patient's eye isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to preserve the outer nuclear layer, wherein the isolated umbilicus-derived cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

10. The method of claim 9 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141; and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

11. The method of claim 10 , wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

12. The method of claim 9 , wherein the isolated umbilicus-derived cells are expanded in culture prior to administering to the interior of the patient's eye.

13. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered with at least one other agent.

14. The method of claim 13 , wherein the at least one other agent is administered simultaneously with, or before, or after, the isolated umbilicus-derived cells.

15. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered through a cannula or from a device inserted in the patient's eye.

16. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered by insertion of a matrix or scaffold containing the cells.

Assignees

• Depuy Synthes Products Inc

Inventors

• Mistry Sanjay
• Messina Darin J

Classifications

• C12N5/0605 Primary

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• C12N2509/00

  Methods for the dissociation of cells, e.g. specific use of enzymes · CPC title

• C12N2502/02

  embryonic cells · CPC title

• C12N5/0607

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title

• C12N2506/03

  from non-embryonic pluripotent stem cells · CPC title